AJCN Tufts Nutrition Symposium, Boston & Online Sept 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Germain, N.
Right arrow Articles by Estour, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Germain, N.
Right arrow Articles by Estour, B.
Agricola
Right arrow Articles by Germain, N.
Right arrow Articles by Estour, B.
American Journal of Clinical Nutrition, Vol. 85, No. 4, 967-971, April 2007
© 2007 American Society for Nutrition

ORIGINAL RESEARCH COMMUNICATION

Constitutional thinness and lean anorexia nervosa display opposite concentrations of peptide YY, glucagon-like peptide 1, ghrelin, and leptin1,2

Natacha Germain, Bogdan Galusca, Carel W Le Roux, Cecile Bossu, Mohammad A Ghatei, Francois Lang, Stephen R Bloom and Bruno Estour

1 From the Departments of Endocrinology (NG, BG, CB, and BE) and Psychiatry (FL), CHU Saint Etienne, St Etienne, France, and Endocrine Unit, Imperial College Faculty of Medicine, Hammersmith Hospital, London, United Kingdom (CWLR, MAG, and SRB)

2 Address reprint requests to B Estour, Service d'Endocrinologie Diabète et Maladies Métaboliques, Hôpital Bellevue, CHU Saint Etienne, 42055 St Etienne Cedex 02, France. E-mail: bruno.estour{at}chu-st-etienne.fr.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Background:Food intake is controlled by the arcuate nucleus through integration of peripheral hormonal signals such as leptin, ghrelin, peptide YY (PYY), and glucagon-like peptide 1 (GLP-1). The most common condition resulting in underweight young women in the developed world is restrictive anorexia nervosa (AN). However, constitutional thinness (CT) is also known to exist in the same low-weight range. Women with CT have normal menstrual periods and do not have the psychological or hormonal features of AN. Little is currently known about regulation of food intake in subjects with CT.

Objective:We tested the hypothesis that concentrations of leptin, ghrelin, PYY, and GLP-1 in persons with AN are significantly different from those in persons with CT.

Design:Concentrations of PYY, GLP-1, ghrelin, and leptin were measured in 3 groups of young women: normal weight (n = 7), CT (n = 10), and AN (n = 12). Samples were collected every 4 h for 24 h.

Results:PYY concentrations were significantly higher in CT subjects than in AN or control subjects. GLP-1 concentrations were significantly higher in AN than in CT subjects, whereas ghrelin was significantly higher in AN subjects than in control and CT subjects. CT subjects had the lowest ghrelin concentrations. Leptin concentrations were significantly lower in AN subjects. PYY and leptin circadian variations were not significantly different between CT and control subjects, whereas these profiles were blunted in AN subjects.

Conclusions:Orexigenic and anorexigenic hormones in CT contrast with an adaptative profile characterizing AN. The hormones appear to be valuable biomarkers for distinguishing these 2 categories of severely underweight subjects.

Key Words: Constitutional thinness • anorexia nervosa • peptide YY • ghrelin • glucagon-like peptide 1 • leptin


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Appetite is controlled by the arcuate nucleus through integration of peripheral hormonal and metabolic signals. Ghrelin, the only orexigenic hormone, is secreted from the stomach (1) with concentrations peaking preprandially. Ghrelin plays a role in meal initiation by direct activation of medial arcuate nucleus neurons (2). Peptide YY (PYY) is released from the L cells in the distal gut (3). PYY has an anorexogenic effect, as evidenced by a reduction in caloric intake in humans and other mammals after the exogenous administration of PYY3-36 (4). Glucagon-like peptide 1 (GLP-1), which is also released from the endocrine L cells in the distal gut, acts as an incretin (5) and also reduces food intake (6). Leptin is an adipose tissue–derived hormone that suppresses appetite by inhibiting neuropeptide Y gene expression in the hypothalamic arcuate nucleus (7).

Fasting concentrations of ghrelin are decreased in obesity (8) and increased in anorexia nervosa (AN) (8, 9). Ghrelin concentrations decrease after weight gain in patients with AN (9, 10) and increase after weight loss in obese subjects (11). PYY is low in obese subjects (12), but conflicting results have been reported for PYY in AN (13-15). Circulating GLP-1 was found to be low both in obesity and in AN (16). Leptin concentrations correlate with adipocyte mass and are low in starvation and elevated in obesity (17).

The World Health Organization has suggested 3 underweight categories: grade 1 [mild underweight; body mass index (BMI; in kg/m2): 17–18.5], grade 2 (moderate underweight; BMI: 16–16.9), and grade 3 (severe underweight; BMI: < 16) (18). The most common reason for young women in the developed world to be underweight is restrictive AN (19). We have previously defined a group of women with constitutional thinness (CT) who satisfied the World Health Organization's definition for moderate-to-severe underweight (BMI: 13–16.9) (10). This group of CT women does not have psychological or hormonal features of AN and displays normal menstruation (20), thyroid function (21), and insulin sensitivity (22). The body weight of persons with CT has always been in the lower centiles for age, sex, and ethnicity. Thus, patients with CT are a variant of normal (23).

We hypothesized that concentrations of appetite-regulating hormones in CT subjects would be comparable with those of normal-weight subjects, but different from those of patients with AN. In this study, we measured PYY, GLP-1, ghrelin, and leptin in 3 groups of young women, respectively, with CT, AN, and normal BMI as control subjects.


   SUBJECTS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
The local research and ethics committee of Saint Etienne, France, approved the study. All subjects gave written informed consent.

Subjects
The study included 3 age-matched groups of white women: CT, AN, and control subjects. The CT and AN subjects were matched for BMI.

Ten CT subjects were recruited from our outpatient clinic. We used the following criteria: BMI between 14.5 and 16.5, stable weight throughout the postpubertal period, presence of menstrual periods without estroprogestative treatment, and the desire to gain weight as the main reason for medical consultation.

Twelve AN subjects were recruited during initial hospitalization before any therapeutic intervention. All patients met the criteria for AN in the Diagnostic and Statistical Manual of Mental Disorders (24) and had a BMI between 14.5 and 16.5. None of the patients used oral contraceptives, and all presented with secondary amenorrhea for >6 mo. Seven normal-weight control subjects (mean BMI: 20.4 ± 0.9) were matched by age (18–27 y) with the AN and CT subjects.

In the CT and control subjects, all data were collected during the follicular phase of the menstrual cycle. None of the subjects had documented chronic or congenital disease, and none of them were taking any medication.

Sampling
Venous blood samples were collected in dry glass tubes containing EDTA and centrifuged (1500 x g for 10 min at 4 °C), and plasma was divided into aliquots and kept frozen at –80 °C before the assay. After an overnight fast, blood was obtained at 0800 for the measurement of serum insulin-like growth factor I (IGF-I), 17ß-estradiol, free triiodothyronine (T3), follicle-stimulating hormone (FSH), luteinizing hormone (LH), total testosterone, sex hormone–binding globulin (SHBG), and dehydroepiandrosterone sulfate (DHEAS). Samples were collected every 4 h for 24 h (0800, 1200, 1600, 2000, 2400, and 0400) to measure PYY, GLP-1, ghrelin, leptin, growth hormone (GH), and cortisol. Standardized meals were served at 0815, 1215, and 1900 (breakfast: 1600 kJ; lunch: 3300 kJ; dinner: 3300 kJ).

Assays
All samples were assayed simultaneously. PYY-like immunoreactivity was determined with the use of a specific and sensitive radioimmunoassay as previously described (4). The assay recognizes 2 biologically active forms of PYY (PYY3–36 and PYY1–36). There was no cross-reactivity with pancreatic polypeptide, neuropeptide Y, or other known gastrointestinal hormones. GLP-1 immunoreactivity was measured with a specific and sensitive radioimmunoassay. The intraassay CV was <10% (5). Plasma total (acylated and deacylated) ghrelin immunoreactivity was determined by radioimmunoassay (RK-031-30; Phoenix Pharmaceuticals, Belmont, CA). Intraassay CV was <5.3% (14).

Radioimmunoassay was used to measure plasma cortisol (intraassay CV: 7%; normal range: 107–310 nmol/L; Immunotech, Prague, Czech Republic), DHEAS (normal range: 85–225 µg/dL; Beckman-Coulter, San Diego, CA), 17ß-estradiol (manufacturer's reference range during the follicular phase: 30–50 ng/L; Dia Sorin, France), leptin [manufacturer's reference range for a normal BMI (18–25): 3.7–11.1 µg/L; Nichols Institute Diagnostics, San Juan Capistrano, CA], and T3 (manufacturer's reference range: 2.5–5.8 pmol/L; Beckman-Coulter). Immunoradiometric assay was used to measure GH (manufacturer's reference concentration: <5 mU/L; Beckman-Coulter), IGF-I (intraassay CV: 7%; manufacturer's reference range: 107–310 µg/L; Beckman-Coulter), LH (manufacturer's reference range during the follicular phase: 0.5–5 UI/L; Beckman-Coulter), FSH (manufacturer's reference range during the follicular phase: 1.8–10.5 UI/L; Beckman-Coulter), and SHBG (manufacturer's reference range: 20–85 nmol/L; BioMérieux, Lyon, France). Radioimmunoassay (Beckman-Coulter) extraction and chromatography were used to measure testosterone (manufacturer's reference range: 7–65 ng/dL). Free testosterone index was calculated as testosterone divided by SHBG.

Energy intake
The study estimated the food intake during a period of 4 d, including 2 weekdays and a weekend. Dietary records were performed with the use of a photographic reference book, which was previously validated for the Supplementation en Vitamines et Mineraux Antioxydants study (25, 26). A nutritionist met the subjects twice, once to explain the collection of the data and the second time to ensure the accuracy of the collected data.

Body-composition measurements
Dual-energy X-ray absorptiometry (Lunar DPX-L; Lunar Corporation, Madison, WI; CV: <1%) measured the percentage of total body fat mass (FM) and fat-free mass expressed in kilograms (27, 28).

Statistical analysis
All values are presented as means ± SEMs. Analysis of variance (ANOVA) was first used to perform a three-group analysis for variables with a single assessment (BMI, FM, IGF-I, 17ß-estradiol, free T3, FSH, LH, total testosterone, SHBG, and DHEAS). Two-factor (group and time) repeated-measures ANOVA was used for PYY, ghrelin, GLP-1, leptin, GH, and cortisol because 6 determinations within 24 h were performed to evaluate the significance of the main effects of interactions for group and group-by-time interactions. When ANOVA was significant (P < 0.05), we performed post hoc ANOVA tests for comparisons within all groups. One-factor (time) repeated-measures ANOVA was performed to evaluate the circadian variation of appetite-regulating hormones within each group. Adapted post hoc analysis (Tukey's test) was performed with P < 0.05. Pearsons's correlation index was calculated to evaluate the relation between appetite-regulating peptides and FM in the overall group: CT + AN + control subjects. All statistical analyses were performed with STATVIEW 4.5 software (Abacus Concepts Inc, Palo Alto, CA).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Estimates of food intake, body weight composition, and baseline hormone characteristics for the 3 groups are shown in Table 1Go. Despite the significant differences in BMI (P < 0.001) and percentage of FM (P < 0.05) between the CT and control groups, no differences were observed in cortisol, GH, IGF-I, free T3, and 17ß-estradiol. The caloric intake for the CT subjects (7821 ± 850 kJ/d) was not different from the control subjects (8150 ± 958 kJ/d) but was significantly higher than that of the AN patients (4304 ± 625 kJ/d; P < 0.05). The circadian profiles of appetite-regulating hormones are shown in Figure 1Go. The main effect of group within a 2-factor repeated-measures ANOVA was significant (P < 0.05) for PYY, GLP-1, ghrelin, and leptin. Post hoc analysis showed that PYY concentrations were significantly higher in the CT subjects than in the control and AN subjects. GLP-1 was significantly higher in the patients with AN than in the patients with CT, whereas ghrelin was significantly higher in the AN subjects than in the control and CT subjects. The CT subjects had the lowest ghrelin concentrations. The leptin circadian cycle was significantly lower in the AN patients.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Food intake estimates, body-weight composition, and hormones in subjects with anorexia nervosa (AN) or constitutional thinness (CT) and in control subjects1

 

Figure 1
View larger version (19K):
[in this window]
[in a new window]

  		FIGURE 1.. Mean (±SEM) concentrations of plasma peptide YY (PYY), glucagon-like peptide 1 (GLP-1), ghrelin, and leptin at 6 time points in subjects with constitutional thinness (CT) or anorexia nervosa (AN) and in control subjects. Similar cyclic circadian shapes of leptin and PYY were noticed in the CT and control subjects, whereas the profiles were blunted in the AN subjects. Intergroup differences and intragroup circadian variations were evaluated by using a 2-factor repeated-measures ANOVA followed by adequate Tukey's test when the interaction was significant (P < 0.05). Groups with different lowercase letters are significantly different at nadir (*) and peak (**) point values of circadian profiles.

 
The CT and control subjects displayed significant intragroup circadian variations for PYY and leptin concentrations (P < 0.05). Thus, in both groups leptin concentrations peaked at 0400 (P < 0.05 compared with values for 0800, 1200, 1600, and 2000) and reached a nadir at 1200 (P < 0.05 compared with values at 0400, 2000, and 2400). PYY reached the lowest value at 0400 (P < 0.05 compared with values at 0800, 1600, and 2000) and the highest at 1600 (P < 0.05 compared with values at 0400, 1200, and 2400). Within the AN group, the circadian profiles for plasma leptin and PYY were blunted. No significant circadian variation was found for ghrelin or GLP-1 in any of the groups. When relations between appetite-regulating peptides and FM (expressed in kg or %) were evaluated in the 3 groups combined (CT + AN + control), only leptin (r = 0.70, P < 0.001) and ghrelin (r = –0.40, P < 0.001) displayed a significant correlation.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
CT is less prevalent among young underweight women in the developed world because restrictive AN is a more common condition, and the 2 diagnoses can be confused. Indeed, despite a low BMI (14.5–16.5), CT females do not exhibit any abnormal clinical features such as amenorrhea, fear of weight gain, or deranged hormonal values, characteristic of AN patients. The current study provides evidence on the differences of appetite-regulating hormones between CT and AN. The CT subjects were characterized by high PYY concentrations, low ghrelin concentrations, and low-to-normal concentrations of GLP-1 and leptin.

These biological differences could be related to some behavioral and physiologic aspects that contrast CT and AN, with specific reference to their different food intake and psychological profile. We recently showed that, although AN has a negative energy balance, CT subjects display an equilibrated energy metabolism similar to that of control subjects. CT subjects attempt to gain weight, whereas AN patients have a fear of gaining weight (29).

In this context we show for the first time an anorexigenic ratio between PYY and ghrelin despite a normal caloric intake in subjects with CT. Because the plasma ratio of orexigenic to anorexigenic hormones and food intake display a reciprocal regulation (2, 4, 30), 2 possible scenarios could account for this unusual combination. First, there may be a primary disturbance in PYY and ghrelin secretion. In this regard, recent reports suggest that PYY deficiency may contribute to the pathogenesis of obesity (31, 32). By analogy we postulate that high PYY concentrations may contribute to CT steadiness. Low ghrelin could also be considered pathophysiologic in CT as suggested by the ghrelin knock-out mice model, which is protected from rapid weight gain induced by early exposure to a high-fat diet (33). This pathophysiologic mechanism should lead to a low-food intake which is not the case in CT subjects. CT subjects often overeat because of their desire to gain weight. Therefore, this anorexigenic ratio could be interpreted as an appropriate response to food intake considered normal when compared with control subjects but abnormally high when related to body weight. The anorexigenic profile of hormones involved in regulation of appetite in CT is biological evidence that can be used to differentiate CT subjects from control subjects.

In the AN subjects, we found an association of low PYY, high ghrelin, and low leptin concentrations that could represent an orexigenic adaptative response of the appetite regulation network to a low-food intake. Despite the orexigenic profile, food intake is not increased, leading us to conclude that psychological determinism is predominant in AN. In these subjects the association between elevated ghrelin and low leptin concentrations was reported by us (10) and others (8, 9, 17), whereas recent data on the fasting PYY concentrations of AN patients are conflicting (14, 15). Thus, Stock et al (14) described no differences between AN and control subjects with overall mean plasma PYY values {approx}65 pg/mL. However, Misra et al (15) found PYY to be higher in AN (17.5 pg/mL) than in control (4.3 pg/mL) subjects. Because both studies assessed total PYY, the discrepancies found between these studies were probably due to differences in technique sensitivity. With the use of the same assessment technique, our PYY concentrations in control subjects were similar to those described by Batterham et al (4) and Stock et al (14). PYY concentrations in AN tend to be lower than those of control subjects in 6 determinations made throughout the day. These data need further confirmation. Only one study assessed GLP-1 in young AN patients and found fasting GLP-1 concentrations to be low (16). In the present study, circadian GLP-1 concentrations in the AN group were significantly higher than in the CT group and tended to be higher than in the control subjects. To better characterize the role of GLP-1 in these groups of lean subjects, it may be of interest to study oxyntomodulin, another peptide co-secreted with GLP-1, which is known to inhibit food intake in rodents and humans, exclusively through the GLP-1 receptor (34).

Physiologic gonadal activity is absent in AN and is undamaged in CT. Thus, high ghrelin concentrations and low leptin concentrations, in association with abnormal corticotropin-releasing hormone activity, mediate the suppression of the reproductive system in AN, or in female athletes (35-37). The relatively low concentrations of ghrelin and normal concentrations of leptin and cortisol in CT are in concordance with normal menstruation and normal estradiol concentrations. The variant of AN without amenorrhea recently proposed (38) should be considered as a diagnosis only after excluding CT.

Our study had several limitations. First, total (acylated and deacylated) ghrelin and total (1–36 and 3–36) PYY concentrations were measured. Acylated ghrelin and PYY3-36, the isoforms responsible for appetite regulation, should be assessed to confirm our hypothesis on appetite control. Meanwhile, the relation between PYY or ghrelin variations and those of hunger and fullness remains to be confirmed (39). Conversely, the measurement of total hormones appears sufficient to distinguish CT from AN. Second, 4-h sampling intervals may be too infrequent to precisely identify the peaks and nadirs in the 24-h ghrelin profile (11). However, this method allowed us to detect circadian variations of leptin and PYY in the CT and control subjects and to calculate 24-h averages of these hormones.

We conclude that all of the anorexigenic and orexigenic peptides evaluated in our study (PYY, GLP-1, ghrelin, and leptin) are useful tools for differentiating 2 categories of severe underweight, namely CT, an almost unknown entity, and AN. However, the observed abnormalities in hormonal profiles were insufficient to explain the appetite regulation profile of CT. Further dynamic studies, including food supplementation or PYY neutralization or both, ghrelin enhancement, and consecutive hunger and fullness evaluation, are required.


   ACKNOWLEDGMENTS
 
NG, BG, and BE designed the study. NG, CWLR, and MAG performed the experiment. BG, CWLR, FL, and CB collected the data. NG, BG, MAG, and BE analyzed the data. NG, BG, BE, CWLR, MAG, and SRB wrote the manuscript. None of the authors had any financial support from or any personal interest in any company or organization sponsoring the research, including advisory board affiliations.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656–60.[Medline]
  2. Cummings DE, Frayo RS, Marmonier C, Aubert R, Chapelot D. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab 2004;287:E297–304.[Abstract/Free Full Text]
  3. Greeley GH Jr, Jeng YJ, Gomez G, et al. Evidence for regulation of peptide-YY release by the proximal gut. Endocrinology 1989;124:1438–43.[Abstract/Free Full Text]
  4. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3–36) physiologically inhibits food intake. Nature 2002;418:650–4.[Medline]
  5. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 1987;2:1300–4.[Medline]
  6. Schirra J, Goke B. The physiological role of GLP-1 in human: incretin, ileal brake or more? Regul Pept 2005;128:109–15.[Medline]
  7. Schwartz MW, Seeley RJ, Campfield LA, Burn P, Baskin DG. Identification of targets of leptin action in rat hypothalamus. J Clin Invest 1996;98:1101–6.[Medline]
  8. Soriano-Guillen L, Barrios V, Campos-Barros A, Argente J. Ghrelin levels in obesity and anorexia nervosa: effect of weight reduction or recuperation. J Pediatr 2004;144:36–42.[Medline]
  9. Otto B, Cuntz U, Fruehauf E, et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001;145:669–73.[Abstract]
  10. Tolle V, Kadem M, Bluet-Pajot MT, et al. Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women. J Clin Endocrinol Metab 2003;88:109–16.[Abstract/Free Full Text]
  11. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623–30.[Abstract/Free Full Text]
  12. Alvarez Bartolome M, Borque M, Martinez-Sarmiento J, et al. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 2002;12:324–7.[Medline]
  13. Gendall KA, Kaye WH, Altemus M, McConaha CW, La Via MC. Leptin, neuropeptide Y, and peptide YY in long-term recovered eating disorder patients. Biol Psychiatry 1999;46:292–9.[Medline]
  14. Stock S, Leichner P, Wong AC, et al. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J Clin Endocrinol Metab 2005;90:2161–8.[Abstract/Free Full Text]
  15. Misra M, Miller KK, Tsai P, et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 2006;91:1027–33.[Abstract/Free Full Text]
  16. Tomasik PJ, Sztefko K, Malek A. GLP-1 as a satiety factor in children with eating disorders. Horm Metab Res 2002;34:77–80.[Medline]
  17. Grinspoon S, Gulick T, Askari H, et al. Serum leptin levels in women with anorexia nervosa. J Clin Endocrinol Metab 1996;81:3861–3.[Abstract/Free Full Text]
  18. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995;854:1–452.[Medline]
  19. Fisher M, Golden NH, Katzman DK, et al. Eating disorders in adolescents: a background paper. J Adolesc Health 1995;16:420–37.[Medline]
  20. Schneider L, Heard I, Breart G, Henrion R. [Maternal thinness and pregnancy]. Arch Fr Pediatr 1979;36:1068–74 (in French).[Medline]
  21. Paggi A, Di Giovanni N, Natoli A. [Study of thyroid function in constitutionally thin subjects]. Boll Soc Ital Biol Sper 1975;51:1–4 (in Italian).[Medline]
  22. Tagami T, Satoh N, Usui T, Yamada K, Shimatsu A, Kuzuya H. Adiponectin in anorexia nervosa and bulimia nervosa. J Clin Endocrinol Metab 2004;89:1833–7.[Abstract/Free Full Text]
  23. Bulik CM, Allison DB. The genetic epidemiology of thinness. Obes Rev 2001;2:107–15.[Medline]
  24. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
  25. Le Moullec N, Deheeger M, Preziosi P, et al. Validation du manuel photos utilisé pour l'enquête alimentaire de l'Etude SU. VI.MAX. [Validation of the photo manual used for the collection of dietary data in the SU.VI.MAX Study.] Cah Nutr Diet 1996;31:158–64 (in French).
  26. Bertrais S, Galan P, Renault N, Zarebska M, Preziosi P, Hercberg S. Consumption of soup and nutritional intake in French adults: consequences for nutritional status. J Hum Nutr Diet 2001;14:121–8.[Medline]
  27. Fuller NJ, Jebb SA, Laskey MA, Coward WA, Elia M. Four-component model for the assessment of body composition in humans: comparison with alternative methods, and evaluation of the density and hydration of fat-free mass. Clin Sci (Lond) 1992;82:687–93.[Medline]
  28. Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr 1990;51:1106–12.[Abstract/Free Full Text]
  29. Bossu C, Galusca B, Normand S, et al. Energy expenditure adjusted for body composition differentiates constitutional thinness from both normal subjects and anorexia nervosa. Am J Physiol Endocrinol Metab 2007;292:E132–7.[Abstract/Free Full Text]
  30. Feinle-Bisset C, Patterson M, Ghatei MA, Bloom SR, Horowitz M. Fat digestion is required for the suppression of ghrelin and stimulation of peptide YY and pancreatic polypeptide secretion by intraduodenal lipid. Am J Physiol Endocrinol Metab 2005;289:E948–53.[Abstract/Free Full Text]
  31. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3–36. N Engl J Med 2003;349:941–8.[Abstract/Free Full Text]
  32. Bacha F, Arslanian SA. Ghrelin and peptide YY in youth: are there race-related differences? J Clin Endocrinol Metab 2006;91:3117–22.[Abstract/Free Full Text]
  33. Wortley KE, del Rincon JP, Murray JD, et al. Absence of ghrelin protects against early-onset obesity. J Clin Invest 2005;115:3573–8.[Medline]
  34. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004;127:546–58.[Medline]
  35. De Souza MJ, Leidy HJ, O'Donnell E, Lasley B, Williams NI. Fasting ghrelin levels in physically active women: relationship with menstrual disturbances and metabolic hormones. J Clin Endocrinol Metab 2004;89:3536–42.[Abstract/Free Full Text]
  36. Holtkamp K, Mika C, Grzella I, et al. Reproductive function during weight gain in anorexia nervosa. Leptin represents a metabolic gate to gonadotropin secretion. J Neural Transm 2003;110:427–35.[Medline]
  37. Norman RL. Corticotropin-releasing hormone effects on luteinizing hormone and cortisol secretion in intact female rhesus macaques. Biol Reprod 1994;50:949–55.[Abstract]
  38. Mitchell JE, Cook-Myers T, Wonderlich SA. Diagnostic criteria for anorexia nervosa: looking ahead to DSM-V. Int J Eat Disord 2005;37(suppl):S95–7.[Medline]
  39. Chanoine JP. Editorial: individual differences in the hormonal control of appetite: a step toward a (more) successful treatment of childhood overweight? J Clin Endocrinol Metab 2006;91:2864–6.[Free Full Text]
Received for publication September 19, 2006. Accepted for publication November 15, 2006.




This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
R P Vincent and C W le Roux
The satiety hormone peptide YY as a regulator of appetite
J. Clin. Pathol., May 1, 2008; 61(5): 548 - 552.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. R Vulliemoz, E. Xiao, L. Xia-Zhang, J. Rivier, and M. Ferin
Astressin B, a Nonselective Corticotropin-Releasing Hormone Receptor Antagonist, Prevents the Inhibitory Effect of Ghrelin on Luteinizing Hormone Pulse Frequency in the Ovariectomized Rhesus Monkey
Endocrinology, March 1, 2008; 149(3): 869 - 874.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Germain, N.
Right arrow Articles by Estour, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Germain, N.
Right arrow Articles by Estour, B.
Agricola
Right arrow Articles by Germain, N.
Right arrow Articles by Estour, B.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS